<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01255371</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12221 ALISA</org_study_id>
    <secondary_id>IP.07.33011.004</secondary_id>
    <nct_id>NCT01255371</nct_id>
  </id_info>
  <brief_title>A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir</brief_title>
  <acronym>ALISA</acronym>
  <official_title>A Multicenter Phase III Trial of Second-line Antiretroviral Treatment Strategies in African Adults (Tanzania Ans South Africa) Using Atazanavir or Lopinavir/Ritonavir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European and Developing Countries Clinical Trials Partnership (EDCTP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Recherche pour le Developpement, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Limpopo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NIMR-Mbeya Medical Research Program (MMRP)/ Mbeya Referral Hospital, Tanzania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the well recognized context of HIV infection chronicity, it is now crucial to identify and
      evaluate effective, well tolerated and affordable second line regimen in resources limited
      countries where patients often change treatment after a long period of viral replication
      while on first line regimen.

      This multicentre international, randomized, non-blinded phase III trial aim to demonstrate
      the non-inferiority of a generic lamivudine-tenofovir-atazanavir/ritonavir regimen (daily
      intake) as compared to a standard emtricitabine-tenofovir-lopinavir/ritonavir (twice daily
      intake)regimen for second line HIV-1 treatment. by stratifying on the viral load level
      (between 1000 and 5000 copies/mL versus &gt; 5000 copies/mL) at inclusion, this trial will also
      allow to evaluate the optimum moment for instituting the second-line treatment.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    drug procurement issues
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virological response</measure>
    <time_frame>48 weeks</time_frame>
    <description>Proportion of patients with plasma HIV RNA &lt; 50 copies/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virological response</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Proportion of patients with plasma HIV RNA &lt; 400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral resistance</measure>
    <time_frame>12, 24 and 48 weeks</time_frame>
    <description>Incidence of resistance mutations after treatment failure (HIV RNA &lt; 1000 copies/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical course of HIV infection</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Mortality, occurence of clinical events stage 3 or 4 (WHO classification), immune reconstitution sundrome, non-AIDS clinical events including bacterial infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance assessment</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>Proportion of adverse events related to antiretroviral treatment, proportion of treatement discontinuations due to antiretroviral side effect, variation of biological parameters and metabolic markers between second line antiretroviral initiation and 24/48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence assessment</measure>
    <time_frame>At each protocol visit : week 2, 4, 12, 24, 36 and 48</time_frame>
    <description>Measurement of pills consumption at each visit, face-to-face questionnaire with the pharmacist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B evaluation</measure>
    <time_frame>At entry</time_frame>
    <description>Prevalence of HBs AG, HBe Ag, HBV viremia, and HBV asociated drug resistance mutations at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic response</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>Variation of circulating total and CD4+ lymphocyte count between second line treatment initiation and 24 weeks/48 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Arm A : Lopinavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Emtricitabine/tenofovir :
TDF300mg.FTC200mg (Fixed Dose Combination)
1 tablet per day
Lopinavir/ritonavir :
LPV200mg/RTV50mg
2 tablets twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B : Atazanavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lamivudine/tenofovir :
3TC300mg/TDF300mg (Fixed Dose Combination)
1 tablet per day
Atazanavir/ritonavir :
ATV300mg/RTV100mg
2 tablets once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir</intervention_name>
    <description>Evaluation of second line antiretroviral regimen including boosted lopinavir</description>
    <arm_group_label>Arm A : Lopinavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <description>Evaluation of second line antiretroviral regimen including boosted atazanavir</description>
    <arm_group_label>Arm B : Atazanavir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 and above

          -  out patient

          -  documented HIV-1 infection

          -  first line treatment failure:

               -  after first-line antiretroviral treatment with a combination including a
                  non-nucleoside reverse transcriptase inhibitor and two nucleoside reverse
                  transcriptase inhibitors

               -  two measurements of plasma HIV RNA levels &gt; 1000 copies/mL after at least 6
                  months of uninterrupted treatment or without any major modification

          -  satisfactory compliance (&gt;80%) to 1st line antiretroviral treatment

          -  signed informed consent

          -  agreement for contraception for women of childbearing age

        Exclusion Criteria:

          -  HIV-2 infection or HIV-1/HIV-2 coinfection

          -  uncontrolled, ongoing opportunistic infection or of any severe or progressive disease
             including active TB

          -  first line antiretroviral treatment with a protease inhibitor or tenofovir

          -  ongoing treatment with rifampicin

          -  severe hepatic insufficiency (PT &lt; 50%)

          -  ALT &lt; 3 times the upper limit of normal

          -  creatinine clearance calculated by Cockcroft's formula &lt; 50 mL/min

          -  Hb &lt;=8 g/dL; platelets &lt; 50,000 cells/mm3; neutrophils &lt; 500 cells/mm3

          -  pregnancy and lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Delaporte</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Recherche pour le Developpement, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Issakwisa Mwakyula</last_name>
    <role>Principal Investigator</role>
    <affiliation>NIMR-Mbeya Medical Research Program-Mbeya Referral Hospital, Tanzania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mzileni O Mogiyana</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Limpopo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandra Calmy</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Geneva, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tshepang clinic, Limpopo University</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIMR-Mbeya Medical Research Program-Mbeya Referral Hospital</name>
      <address>
        <city>Mbeya</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2010</study_first_submitted>
  <study_first_submitted_qc>December 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2010</study_first_posted>
  <last_update_submitted>November 7, 2012</last_update_submitted>
  <last_update_submitted_qc>November 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Second line antiretroviral treatment</keyword>
  <keyword>Sub saharian Africa</keyword>
  <keyword>Generic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

